Heron Therapeutics (HRTX) Finished Goods: 2016-2025
Historic Finished Goods for Heron Therapeutics (HRTX) over the last 8 years, with Sep 2025 value amounting to $10.9 million.
- Heron Therapeutics' Finished Goods rose 60.79% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 60.79%. This contributed to the annual value of $6.2 million for FY2024, which is 37.11% down from last year.
- Heron Therapeutics' Finished Goods amounted to $10.9 million in Q3 2025, which was down 0.96% from $11.0 million recorded in Q2 2025.
- Heron Therapeutics' Finished Goods' 5-year high stood at $22.0 million during Q3 2022, with a 5-year trough of $6.2 million in Q4 2024.
- In the last 3 years, Heron Therapeutics' Finished Goods had a median value of $9.9 million in 2023 and averaged $10.3 million.
- The largest annual percentage gain for Heron Therapeutics' Finished Goods in the last 5 years was 319.60% (2021), contrasted with its biggest fall of 61.07% (2021).
- Over the past 5 years, Heron Therapeutics' Finished Goods (Quarterly) stood at $6.3 million in 2021, then surged by 199.22% to $18.7 million in 2022, then tumbled by 47.00% to $9.9 million in 2023, then crashed by 37.11% to $6.2 million in 2024, then surged by 60.79% to $10.9 million in 2025.
- Its Finished Goods stands at $10.9 million for Q3 2025, versus $11.0 million for Q2 2025 and $8.5 million for Q1 2025.